Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists

Autores de IIS La Fe

• Hortensia Ferrero Chafer

  Autor

• Carmen Maria Garcia Pascual

  Autor

• Concepcion Morales Garcia

  Autor

• Carlos Simon Valles

  Autor

• Francisco Gaytan Luna

  Autor

• Antonio Pellicer Martínez

  Autor

Participantes ajenos a IIS La Fe

• Gaytán M
• Gómez R

Grupos

• Medicina Fetal y Reproductiva

Abstract

Objective: To explore whether a dopamine receptor 2 agonist (D2-ag) can prevent ovarian hyperstimulation syndrome (OHSS) in a rat model by decreasing ovarian vascular endothelial growth factor (VEGF) production. Design: Experimental study in an OHSS animal model. Setting: University-affiliated infertility center. Patient(s): Immature Wistar rats. Intervention(s): Immature rats were stimulated with gonadotropins to mimic OHSS and treated with a D2-ag and/or D2-antagonists (D2-ant). Vascular permeability (VP) was measured at the endpoint, and ovaries were collected to assess the effects of these drugs on VEGF production. Main Outcome Measure(s): VP was estimated by measuring the peritoneal extravasation of a previously injected dye. Ovarian VEGF mRNA expression and VEGF protein levels were assessed by quantitative real-time PCR and Western blots, respectively. Result(s): The D2-ag exerted a reduction in VP that was associated with a drastic decrease in VEGF protein production in OHSS rat ovaries. The effects of this D2-ag on VP and VEGF protein levels were partially reversed by concomitant administration of a D2-ant. Ovarian VEGF mRNA expression levels were unaffected by these drugs in OHSS rats. Conclusion(s): D2-ags prevent increased VP in OHSS rats by decreasing ovarian VEGF production, very likely through a D2-mediated post-transcriptional mechanism. Given the dose-dependent inhibitory effect of D2-ags on ovarian VEGF production reported herein, we infer that current OHSS therapies used in humans may be improved by increasing the intraovarian concentration of D2-ags in these patients. ((C)2014 by American Society for Reproductive Medicine.)

Keywords

• OHSS; VEGF; animal model; dopamine receptor 2 agonists